Breakoutwatch Weekly Summary 10/14/2023

You are receiving this email because you are or were a BreakoutWatch.com subscriber, or have subscribed to our weekly newsletter.
To read this newsletter on the site, click here: Newsletter .

Contents

The newsletter has been absent for a few weeks as I have concentrated on correcting some data problems introduced by a hack of the database. I believe all stock data is now correct and watchlist filters are working again. Next week I depart for 4 weeks on a European vacation but will try to produce this newsletter remotely.

Market Summary

Stocks mixed as earnings season kicks off

The major indexes ended mixed as investors weighed inflation data against dovish signals from Federal Reserve officials. Large-cap value stocks outperformed, helped by earnings beats from Citigroup, Wells Fargo, and JPMorgan Chase. The banking giants kicked off the unofficial start to third-quarter earnings reporting season on a positive note, as their profits got a boost from higher interest rates. [more...]

Major Index Performance

Dow Jones
Last Close 0
Wk. Gain -100 %
Yr. Gain -100 %
Trend Down
Dow Jones
S&P 500
Last Close 0
Wk. Gain -100 %
Yr. Gain -100 %
Trend Down
S&P 500
NASDAQ Comp.
Last Close 0
Wk. Gain -100 %
Yr. Gain -100 %
Trend Down
NASDAQ Comp.
Russell 2000
Last Close 0
Wk. Gain -100 %
Yr. Gain -100 %
Trend Down
Russell 2000

Performance by Sector

Sector Wk. Change % Yr. Change % Trend
Consumer Discretionary 0.33 21.67 Down
Consumer Staples 0.33 -8.05 Down
Energy 1.8 5.02 Down
Finance 1.03 -2.81 Down
Health Care 0.19 -4.67 Down
Industrials 0.37 6.77 Down
Technology 0.48 33.77 Up
Materials -0.2 -0.56 Down
REIT 2.23 -8.47 Down
Telecom 0.22 31.74 Up
Utilities 3.46 -17.4 Down

Breakouts This Week Still Within 5% of Breakout Price (Limit 20 top C Score)

Watchlist Symbol Company Industry C Score* % Gain
CWH LPG Dorian LPG Ltd. Biotechnology 82.2 % 0.8 %
DB INSW International Seaways, Inc. Software - Application 80.3 % 0.6 %
SQZ AVGO Broadcom Inc. Semiconductors 77.6 % 3.2 %
SQZ PLUS ePlus inc. Software - Application 76.9 % 1.7 %
SQZ VRTX Vertex Pharmaceuticals Inco Biotechnology 75.8 % 2.9 %
SQZ JPM JP Morgan Chase & Co. Banks - Diversified 75.4 % 1.5 %
DB UNH UnitedHealth Group Inco Healthcare Plans 74.9 % 1.7 %
CWH RNR RenaissanceRe Holdings Ltd. Insurance - Reinsurance 74.1 % 2.6 %
CWH DRS Leonardo DRS, Inc. Biotechnology 72.1 % 1.2 %
SQZ AMWD American Woodmark Corporation Asset Management 71.9 % 1.4 %
SQZ AVPT AvePoint, Inc. Software - Infrastructure 70.8 % 3 %
SQZ VMW Vmware, Inc. Software - Infrastructure 70.8 % 3.7 %
SQZ COST Costco Wholesale Corporation Discount Stores 70.2 % 0.5 %
SQZ CRVL CorVel Corp. Insurance Brokers 69.9 % 0.2 %
SQZ CTRE CareTrust REIT, Inc. REIT - Healthcare Facilities 68.7 % 1.7 %
SQZ RELY Remitly Global, Inc. Software - Infrastructure 66.5 % 2.9 %
SQZ LBRDA Liberty Broadband Corporation Telecom Services 64.2 % 0.3 %
SQZ BLTE Belite Bio, Inc Biotechnology 60.5 % 0.3 %
SQZ DBD Diebold Nixdorf Inco Software - Application 41.8 % 1 %
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Breakdowns within 5% of Breakdown Price

Watchlist Symbol Company Industry C Score* % Loss
SS ITI Iteris, Inc. Communication Equipment 75.2 % -0.7 %
SS STN Stantec Inc Semiconductors 74.9 % -2 %
SS SXI Standex International Corporation Specialty Industrial Machinery 71.9 % -3.5 %
SS KOP Koppers Holdings Inc. Specialty Chemicals 71.2 % -2.3 %
SS PINS Pinterest, Inc. REIT - Retail 64.7 % -2.4 %
SS AMD Advanced Micro Devices, Inc. Semiconductors 63.3 % -1 %
SS ZEUS Olympic Steel, Inc. Steel 60.9 % -4.6 %
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Cup and Handle Chart of the Week

Aug. 16, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the achievement of First-Patient-In for the company-sponsored Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM) patients.